Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Vobra-duo is discontinued at long last.
The company’s matching strategy for CB-010 will soon be put to the test.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
While Sutro shows why it’s shelved luvelta-T.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
